Brain biopsy and pathological diagnosis for drug‐associated progressive multifocal leukoencephalopathy (PML) with inflammatory reactions
Pathology International · 2024
DOI: 10.1111/pin.13492 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathology International, 2024. Verfasst von Yukiko Shishido-Hara. Beteiligte Einrichtung: Department of Pathology and Applied Neurobiology, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Leukoencephalopathy, Progressive Multifocal, Brain, JC Virus. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system caused by JC virus (JCV) infection. Although recognized as an AIDS complication in the 1980s, PML has emerged as a serious adverse event of immunosuppressive therapies since 2005, particularly disease‐modifying drugs (DMDs) for multiple sclerosis (MS). PML can also occur in patients with collagenous diseases receiving steroid therapy or with age‐related immunosuppression. In some cases, the etiology of immunosuppression remains unclear. These cases often present with early manifestations of PML, which, while common, are less well recognized, as PML was identified at more advanced stages in AIDS‐related cases. Early diagnosis poses difficulty due to unfamiliar magnetic resonance (MR) images and low viral loads in cerebrospinal fluid (CSF), and brain biopsy may be conducted. This review summarizes the PML pathology identified through biopsy. Early cytopathological changes of JCV‐infected cells, with the importance of dot‐shaped inclusions associated with promyelocytic leukemia nuclear bodies (PML‐NBs), are described. The variability of host immune responses, including PML immune reconstitution inflammatory syndrome (PML‐IRIS), is addressed. The potential role of immune checkpoint inhibitors (ICIs), such as pembrolizumab, is also explored. Understanding the pathology of early PML helps to optimize diagnostic strategies and therapeutic interventions, ultimately improving prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Applied Neurobiology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Shishido-Hara, Y. (2024). Brain biopsy and pathological diagnosis for drug‐associated progressive multifocal leukoencephalopathy (PML) with inflammatory reactions. Pathology International. https://doi.org/10.1111/pin.13492
Vancouver
Shishido-Hara Y. Brain biopsy and pathological diagnosis for drug‐associated progressive multifocal leukoencephalopathy (PML) with inflammatory reactions. Pathology International. 2024. doi:10.1111/pin.13492
BibTeX
@article{ShishidoHara2024,
author = {Shishido-Hara, Yukiko},
title = {Brain biopsy and pathological diagnosis for drug‐associated progressive multifocal leukoencephalopathy (PML) with inflammatory reactions},
journal = {Pathology International},
year = {2024},
doi = {10.1111/pin.13492}
}
EUVIMED